Eli Lilly and Company (NYSE:LLY) Shares Purchased by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 93,300 shares of the company’s stock after acquiring an additional 3,500 shares during the period. Eli Lilly and Company makes up approximately 0.4% of Ilmarinen Mutual Pension Insurance Co’s portfolio, making the stock its 20th biggest holding. Ilmarinen Mutual Pension Insurance Co’s holdings in Eli Lilly and Company were worth $32,041,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Oxler Private Wealth LLC boosted its stake in shares of Eli Lilly and Company by 0.4% during the first quarter. Oxler Private Wealth LLC now owns 6,050 shares of the company’s stock valued at $2,078,000 after acquiring an additional 24 shares during the last quarter. Missouri Trust & Investment Co boosted its stake in shares of Eli Lilly and Company by 3.2% during the first quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock valued at $266,000 after acquiring an additional 24 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its stake in shares of Eli Lilly and Company by 0.6% during the first quarter. Silvercrest Asset Management Group LLC now owns 4,331 shares of the company’s stock valued at $1,487,000 after acquiring an additional 25 shares during the last quarter. Cora Capital Advisors LLC lifted its position in Eli Lilly and Company by 2.8% during the first quarter. Cora Capital Advisors LLC now owns 956 shares of the company’s stock worth $328,000 after buying an additional 26 shares during the period. Finally, Sittner & Nelson LLC lifted its position in Eli Lilly and Company by 2.7% during the first quarter. Sittner & Nelson LLC now owns 1,003 shares of the company’s stock worth $344,000 after buying an additional 26 shares during the period. Institutional investors and hedge funds own 81.38% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Jefferies Financial Group upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their target price for the stock from $408.00 to $615.00 in a research report on Tuesday, August 8th. BMO Capital Markets increased their target price on Eli Lilly and Company from $565.00 to $633.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 9th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $500.00 to $615.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 8th. 22nd Century Group reiterated a “maintains” rating on shares of Eli Lilly and Company in a research report on Tuesday, June 27th. Finally, Credit Suisse Group raised their price objective on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $532.78.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 34,156 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $454.08, for a total value of $15,509,556.48. Following the completion of the transaction, the insider now owns 101,387,286 shares in the company, valued at approximately $46,037,938,826.88. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 34,156 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $454.08, for a total value of $15,509,556.48. Following the sale, the insider now owns 101,387,286 shares of the company’s stock, valued at approximately $46,037,938,826.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $546.51, for a total value of $327,906.00. Following the completion of the sale, the chief accounting officer now directly owns 5,378 shares in the company, valued at approximately $2,939,130.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,036,514 shares of company stock worth $21,107,445,590. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $599.54 on Wednesday. Eli Lilly and Company has a fifty-two week low of $296.32 and a fifty-two week high of $601.13. The business has a 50 day moving average price of $504.85 and a two-hundred day moving average price of $433.48. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. The firm has a market cap of $569.14 billion, a PE ratio of 83.39, a price-to-earnings-growth ratio of 2.36 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The firm had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. During the same quarter last year, the firm earned $1.25 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. Sell-side analysts expect that Eli Lilly and Company will post 9.83 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were given a $1.13 dividend. The ex-dividend date was Monday, August 14th. This represents a $4.52 annualized dividend and a dividend yield of 0.75%. Eli Lilly and Company’s payout ratio is 62.87%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.